Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

abstract：AIMS:Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is depende...

journal_title：Pharmacogenomics

authors： Gordon MA,Zhang W,Yang D,Iqbal S,El-Khouiery A,Nagashima F,Lurje G,Labonte M,Wilson P,Sherrod A,Ladner RD,Lenz HJ

更新日期：2011-01-01 00:00:00

abstract：:The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

journal_title：Pharmacogenomics

authors： Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

更新日期：2012-11-01 00:00:00

abstract：:Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

journal_title：Pharmacogenomics

authors： Vucic EA,Brown CJ,Lam WL

更新日期：2008-02-01 00:00:00

abstract：AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...

journal_title：Pharmacogenomics

authors： Iamjan SA,Thanoi S,Watiktinkorn P,Nudmamud-Thanoi S,Reynolds GP

更新日期：2015-01-01 00:00:00

abstract：:The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advan...

journal_title：Pharmacogenomics

authors： Esplin ED,Oei L,Snyder MP

更新日期：2014-11-01 00:00:00

abstract：:Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

journal_title：Pharmacogenomics

authors： Zuiverloon TC,Theodorescu D

更新日期：2017-08-01 00:00:00

abstract：:Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients...

journal_title：Pharmacogenomics

authors： Xiang Q,Liu Z,Lu Y,Mao J,Chen S,Zhao X,Zhou S,Xie Q,Wang Z,Mu G,Jiang J,Gong Y,Cui Y

更新日期：2020-01-01 00:00:00

abstract：:For the last 40 years, 5-fluorouracil (5-FU) has remained the treatment of choice in both the adjuvant and advanced treatment of colorectal cancer (CRC). However, 5-FU monotherapy produces response rates of only 10-20% in the advanced setting. 5-FU has been combined with newer agents, such as oxaliplatin and irinoteca...

journal_title：Pharmacogenomics

authors： Allen WL,Johnston PG

更新日期：2005-09-01 00:00:00

abstract：INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...

journal_title：Pharmacogenomics

authors： Kealey C,Chen Z,Christie J,Thorn CF,Whitehead AS,Price M,Samaha FF,Kimmel SE

更新日期：2007-03-01 00:00:00

abstract：:Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

journal_title：Pharmacogenomics

authors： Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

更新日期：2021-01-01 00:00:00

abstract：AIMS:To determine the extent of pharmacogenomics instruction at US and Canadian medical schools, characterize perceptions of curricular coverage, identify curricular resources and compare responses with similar studies conducted in US pharmacy schools and British medical schools. MATERIALS & METHODS:A survey was sent ...

journal_title：Pharmacogenomics

authors： Green JS,O'Brien TJ,Chiappinelli VA,Harralson AF

更新日期：2010-09-01 00:00:00

abstract：:Cancer patients frequently suffer from disease- and treatment-related pain, nausea and depression, which severely reduces patients' quality of life. It is critical that clinicians are aware of drug-gene interactions and recognize the utility of applying pharmacogenetic information to personalize and improve supportive...

journal_title：Pharmacogenomics

authors： Andersen RL,Johnson DJ,Patel JN

更新日期：2016-03-01 00:00:00

abstract：:Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

journal_title：Pharmacogenomics

authors： Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

更新日期：2017-11-01 00:00:00

abstract：:The multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette (ABC) superfamily of membrane transporters. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multi-drug resistance,...

journal_title：Pharmacogenomics

authors： Sakaeda T,Nakamura T,Okumura K

更新日期：2003-07-01 00:00:00

abstract：:Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

journal_title：Pharmacogenomics

authors： Taylor DR,Kennedy MA

更新日期：2002-03-01 00:00:00

abstract：:Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

journal_title：Pharmacogenomics

authors： Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

更新日期：2019-08-01 00:00:00

abstract：:Mother-to-child-transmission rates of HIV in the absence of any intervention range between 20 and 45%. However, the provision of antiretroviral drugs (ARVs) during pregnancy, delivery and breastfeeding can reduce HIV transmission to less than 2%. Physiological changes during pregnancy can influence ARV disposition. As...

journal_title：Pharmacogenomics

authors： Olagunju A,Owen A,Cressey TR

更新日期：2012-10-01 00:00:00

abstract：:The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...

journal_title：Pharmacogenomics

authors： Thallinger GG,Trajanoski S,Stocker G,Trajanoski Z

更新日期：2002-09-01 00:00:00

abstract：:Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

journal_title：Pharmacogenomics

authors： Wiltshire T,Dong OM

更新日期：2018-04-01 00:00:00

abstract：INTRODUCTION:One of the causes of long-term morbidity associated with the treatment of acute lymphoblastic leukemia (ALL) is late neurotoxicity manifesting as impairment of higher cognitive functions. Cranial radiation therapy (CRT) and chemotherapeutic agents, particularly methotrexate (MTX), are often suggested to be...

journal_title：Pharmacogenomics

authors： Krajinovic M,Robaey P,Chiasson S,Lemieux-Blanchard E,Rouillard M,Primeau M,Bournissen FG,Moghrabi A

更新日期：2005-04-01 00:00:00

abstract：:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

journal_title：Pharmacogenomics

authors： Andrade RJ,Robles M,Ulzurrun E,Lucena MI

更新日期：2009-09-01 00:00:00

abstract：:Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...

journal_title：Pharmacogenomics

authors： Molokhia M,McKeigue P

更新日期：2006-06-01 00:00:00

abstract：:Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...

journal_title：Pharmacogenomics

authors： Ferrell PB Jr,McLeod HL

更新日期：2008-10-01 00:00:00

abstract：:The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...

journal_title：Pharmacogenomics

authors： Watmuff B,Liu B,Karmacharya R

更新日期：2017-04-01 00:00:00

abstract：AIM:The present study explored the integrative effect of genes encoding methadone pharmacokinetic and pharmacodynamic pathways on methadone maintenance doses in Han Chinese Patients. MATERIALS & METHODS:Genomic DNA was extracted from 321 opioid-dependent patients and 202 healthy controls, and realtime-PCR and PCR-RFLP...

journal_title：Pharmacogenomics

authors： Hung CC,Chiou MH,Huang BH,Hsieh YW,Hsieh TJ,Huang CL,Lane HY

更新日期：2011-11-01 00:00:00

abstract：:The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

journal_title：Pharmacogenomics

authors： Huang S

更新日期：2001-08-01 00:00:00

abstract：AIM:To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS:DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitaglipti...

journal_title：Pharmacogenomics

authors： Jamaluddin JL,Huri HZ,Vethakkan SR

更新日期：2016-06-01 00:00:00

abstract：AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...

journal_title：Pharmacogenomics

authors： Lemos C,Giovannetti E,Zucali PA,Assaraf YG,Scheffer GL,van der Straaten T,D'Incecco A,Falcone A,Guchelaar HJ,Danesi R,Santoro A,Giaccone G,Tibaldi C,Peters GJ

更新日期：2011-02-01 00:00:00

abstract：:The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...

journal_title：Pharmacogenomics

authors： van Schie RM,Wadelius MI,Kamali F,Daly AK,Manolopoulos VG,de Boer A,Barallon R,Verhoef TI,Kirchheiner J,Haschke-Becher E,Briz M,Rosendaal FR,Redekop WK,Pirmohamed M,Maitland van der Zee AH

更新日期：2009-10-01 00:00:00

abstract：AIM:Genetic variants contribute to statins' therapeutic variability. SREBF-SCAP pathway is a key player in lipid homeostasis. Hence, effect of SREBF-SCAP polymorphisms on therapeutic response was studied. PATIENTS & METHODS:Metabolic syndrome patients of either sex were prescribed rosuvastatin 10 mg for 24 weeks. Clin...

journal_title：Pharmacogenomics

authors： Rafeeq MM,Habib HS,Murad HAS,Gari MA,Gazzaz ZJ

更新日期：2018-02-01 00:00:00